PITTSBURGH , Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr.

PITTSBURGH, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of  Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), today announced that Bhushan Hardas, MD, MBA, President, Jeune Aesthetics, will participate on the panel titled “State of Aesthetic Industry

PITTSBURGH , Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a

PITTSBURGH , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock.

•  Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEK TM was well tolerated, with no drug-related serious adverse events or discontinuations Biologics License

Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in mice KB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin PITTSBURGH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc.,

–  Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 –  Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete –  Strong balance sheet with September 30, 2021 cash, cash

Topline results anticipated in the fourth quarter of 2021 Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint assessment visits PITTSBURGH , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.

PITTSBURGH , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy

PITTSBURGH , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment